Laura Ludlow, PA
Medical · Topeka, KSNPI 1154301802
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,317 of the $60,731 with a category attached, or 63.1%. Regeneron Healthcare Solutions, Inc. accounts for 78.8% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $25,741, more than ten times the $721 reported in 2021. Among medical clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $150.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$48K
- Jazz Pharmaceuticals Inc.$4K
- Sanofi$3K
- GSK$2K
- AstraZeneca$1K
- Regeneron$1K
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,8655%
- Speaking & faculty fees$38,31763%
- Travel & lodging$9,89816%
- Food & beverage$9,36915%
- Education$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 184 | $47,835 |
| Jazz Pharmaceuticals Inc. | 15 | $3,914 |
| Sanofi | 22 | $2,562 |
| GSK | 74 | $2,106 |
| AstraZeneca | 55 | $1,403 |
| Regeneron | 3 | $1,376 |
| Boehringer Ingelheim | 5 | $291 |
| Harmony Biosciences LLC | 4 | $225 |
| Grifols USA, LLC | 9 | $183 |
| United Therapeutics Corporation | 5 | $124 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $108 |
| Axsome Therapeutics, Inc. | 3 | $88 |
| Insmed, Inc. | 4 | $82 |
| Inspire Medical Systems, Inc. | 1 | $81 |
| Amgen | 3 | $78 |
| Actelion Pharmaceuticals US, Inc. | 3 | $58 |
| Novartis | 3 | $55 |
| Bayer | 2 | $48 |
| Merck | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,731 in reported general payments places this provider in the 95th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $404,260 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 337 | $354,891 |
| NucalaMepolizumab | 44 | $188,485 |
| Dupixent PenDupilumab | 45 | $186,874 |
| Fasenra PenBenralizumab | 19 | $117,913 |
| Spiriva HandihalerTiotropium Bromide | 109 | $109,472 |
| Spiriva RespimatTiotropium Bromide | 92 | $83,395 |
| Incruse ElliptaUmeclidinium Bromide | 96 | $51,444 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $47,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $46,434 |
| SymbicortBudesonide/Formoterol Fumarate | 92 | $44,909 |
| Pirfenidone | 18 | $43,150 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $41,444 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 196 | $40,929 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $40,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $2,106 | $684,233585 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $291 | $528,146176 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,403 | $91,343152 claims |
| MerckDulera | $43 | $17,80234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 205 medical providers in Kansas.
Other medical in Topeka
- Linly StevensOverland Park$111K
- Shana ArnholdShawnee$82K
- Richard AllenbachWichita$70K
- Anita KishOlathe$58K
- Kathryn WelchWichita$32K
- Courtney SteneOverland Park$22K
- Janella DewittOverland Park$19K
- Walter DeanMission$16K
- Jason MengesWichita$15K
- Trang BrownleeWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.